Medicine & Pharmaceuticals News
Hudson Hedge Capital Provides Strategic Development Update on CINV
Hudson Hedge Capital has provided a strategic update concerning Crucial Innovation Inc. ("CINV"), a private company developing an integrated pharmaceutical botanical therapeutics platform. CINV is working to transform regulated plant-derived compounds into standardised active pharmaceutical ingredients, clinically governed formulations and scalable finished-dose medicines. Its developing platform is intended to span cultivation, pharmaceutical-grade processing, formulation, clinical research and regulated patient access. Medical cannabis provides the current commercial foundation, while additional botanical compounds may present longer-term development opportunities. Any product development, therapeutic application or research programme remains subject to scientific validation, successful clinical development and applicable regulatory approvals. Proposed Transaction with Nasdaq-Listed 707 Cayman Holdings On 25 August 2026, Nasdaq-listed 707 Cayman Holdings Limited announced that it had entered into a non-binding term sheet to acquire CINV. According to that announcement, the proposed combination is intended to bring together CINV's botanical therapeutics platform and 707 Cayman Holdings' existing public-market infrastructure. The proposed transaction is not a completed acquisition or confirmed public listing for CINV. It remains subject to satisfactory due diligence, delivery of PCAOB-audited financial statements, execution of definitive agreements and applicable corporate, shareholder, regulatory and Nasdaq approvals. The final transaction structure, valuation, consideration, capital arrangements and allocation of proceeds have not been confirmed. There is no assurance that the transaction will be completed on the terms presently contemplated, within a particular timeframe or at all. Private-Market Reference Information As part of CINV's private capital planning, indicative reference information has included a private share reference price of US$1.09 per share, an indicative company valuation of approximately US$128 million, potential private transaction sizes beginning from approximately US$100,000, and an illustrative future valuation scenario equivalent to US$2.52 per share. These figures are included solely to explain elements of the company's current private-market planning. They have not been independently verified and must not be interpreted as an offer price, public subscription invitation, expected trading price, investment recommendation or guarantee of future value. In particular, the US$2.52 figure represents an illustrative management scenario, not a formal price target, independent valuation opinion or prediction. It depends on numerous assumptions, including operational execution, financing, dilution, regulatory progress, scientific development, market conditions and the structure and completion of future corporate transactions. No assurance can be given that this scenario will be achieved. Private Capital Activity Hudson Hedge Capital has supported CINV's private capital planning and related strategic discussions. Any potential securities transaction will be considered separately from this public announcement and may be made available only through confidential documentation to persons who have first been assessed as eligible under the laws and regulations applicable to them. No person may subscribe for or acquire securities on the basis of this announcement. Any potential transaction will be subject to availability, investor eligibility, appropriate know-your-client and anti-money-laundering checks, satisfactory due diligence and executed definitive documentation. The reference to potential transaction sizes beginning from US$100,000 does not constitute an invitation to invest and does not mean that an investment is available to any particular person or in any particular jurisdiction. Strategic Roadmap CINV's current roadmap includes the continued development of its pharmaceutical botanical platform, expansion of regulated routes to market, advancement of its research infrastructure and completion of the work required in connection with the proposed transaction. These are objectives rather than confirmed outcomes. Their timing and completion will depend on financing, regulatory requirements, scientific and commercial progress, market conditions and other factors outside the control of CINV or Hudson Hedge Capital. Hudson Hedge Capital will continue to monitor the company's progress and expects further factual updates to be issued when material developments have been completed or formally confirmed. About CINV Crucial Innovation Inc. is developing an integrated pharmaceutical botanical therapeutics platform spanning cultivation, GMP processing, formulation, clinical research and regulated patient access. The company's stated mission is to transform regulated plant-derived compounds into standardised APIs, clinically governed formulations and scalable finished-dose medicines. About Hudson Hedge Capital Hudson Hedge Capital is an independent investment and advisory firm headquartered in Dubai. The firm works with private clients, family offices and corporate entities across strategic investment planning, private markets and multi-asset investment strategies. Email directly to m@hudsonhedgecapital.com .
Veneers Dominican Republic Expands Focus on International Patient Services
Global Nest Family Receives 2026 Global Recognition Award for International Family-Building Support
Pure Derma Clinic Highlights Doctor-Led Aesthetic Treatments
- August 24, 2026Medicine & Pharmaceuticals
Creative Biolabs Expands Primary Immune Cell Portfolio for 3D Tumor Microenvironment Modeling
Creative Biolabs has expanded its primary immune cell portfolio to support the development of 3D tumor microenvironment models for immunotherapy and immuno-oncology research. The expanded offering includes circulating and tissue-associated immune cell types that can be incorporated into in vitro co-culture, spheroid, and organoid workflows. Constructing a Stratified In Vitro Immune Network The complexity of the human immune system dictates that simplistic, single-cell-type models may not fully capture the cellular interactions that influence therapeutic responses in vivo . To bridge this translational gap, Creative Biolabs has structured its cell portfolio to support multi-layered, dynamic immune modeling. For assays requiring foundational immune competency and broad-spectrum profiling, researchers can establish reliable baselines using extensively characterized human peripheral blood mononuclear cells (PBMCs) . These robust isolates can provide a useful baseline for immune profiling and selected functional screening applications. However, when experimental protocols demand the precise interrogation of specific mechanistic pathways—such as CAR-T cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), or macrophage polarization—the platform provides immediate access to rigorously purified immune cell subpopulations . This offering includes highly purified and characterized immune cell populations that support more controlled functional assays. Addressing the Tissue-Resident Paradigm in Immuno-Oncology A frequently encountered technical question in advanced 3D tissue modeling concerns the phenotypic discrepancy between systemic circulating immune cells and those situated within solid organ stroma. Specifically, researchers often query why tissue-specific cells are requisite for advanced organoid cultures over standard PBMCs. Creative Biolabs resolves this by integrating specialized tissue-resident immune cells into its portfolio. These cells can retain selected tissue-associated phenotypic and functional characteristics that may be difficult to reproduce using circulating immune cells alone. Utilizing these specialized cells can be particularly valuable for scientists aiming to accurately model solid tumor infiltration, hepatic immune responses, or dermal inflammatory cascades in 3D spatial biology. Expert Insight and Clinical Relevance "The value of advanced 3D tumor models lies in their ability to incorporate more of the cellular complexity found in the tumor microenvironment," said the Director of 3D Cell Technology at Creative Biolabs. "Providing access to both circulating and tissue-associated immune cell populations gives researchers greater flexibility to design fit-for-purpose co-culture models for immuno-oncology studies." The portfolio also emphasizes cell characterization parameters relevant to reproducible 3D culture workflows, including post-thaw viability, HLA typing where applicable, donor information, and lot-level quality documentation. Primary immune cells can help researchers introduce donor-specific immune phenotypes and functional responses into 3D tumor models, adding biological complexity beyond tumor-only cultures. About Creative Biolabs Creative Biolabs is a premier provider of innovative 3D biology and preclinical research solutions. Specializing in advanced in vitro models, the company empowers global researchers with cutting-edge 3D tumor organoids, spheroids, and complex immune co-culture systems.
- August 22, 2026Medicine & Pharmaceuticals
RovithoMed Expands Coordinated Medical Tourism Services for International Patients
RovithoMed , an Istanbul-based medical tourism company, is expanding its coordinated approach to healthcare travel, bringing access to multiple medical disciplines and patient support services together for people considering treatment in Turkey. The company’s network covers dental care, hair restoration, dermatology, facial aesthetics, oculoplastic procedures and plastic aesthetic treatments. RovithoMed also coordinates practical elements of international healthcare travel, including initial consultations, treatment planning, accommodation assistance, airport and local transfers, and post-treatment communication. The approach is intended to give international patients a central point of coordination rather than requiring them to arrange each part of a medical trip independently. “International patients have to consider much more than the procedure itself,” said Mehmet Ebcim, Founder of RovithoMed. “They want to understand who will treat them, how their treatment will be organised and who they can communicate with before and after travelling. Our aim is to bring those elements together in a clearer and more coordinated process.” A Multidisciplinary Network Supporting International Patient Care The RovithoMed network brings together practitioners working across several areas of medical and aesthetic care. Among them is Dr Yıldız Acar Ebcim , MD, FEBO, an ophthalmologist whose practice includes oculoplastic procedures involving the eyelids and surrounding facial area. Procedures coordinated through the network include lower blepharoplasty , subject to individual consultation and assessment by the relevant medical practitioner. The network also includes dermatologist Associate Professor Tuğba Falay Gür, MD, and ENT specialist Halim İş, MD. Dental services are supported by Dt. Saliha Ezgi Akıncı, whose work includes restorative, aesthetic and implant-based dental treatment planning. By bringing different disciplines into the same network, RovithoMed aims to simplify the organisational side of treatment for patients travelling internationally, with individual treatment decisions subject to consultation with the appropriate healthcare professional. Coordinating Treatment Planning and the Wider Medical Travel Process Travelling internationally for healthcare can involve a series of medical and practical decisions. Patients may need to identify an appropriate practitioner, arrange consultations and treatment dates, organise travel and accommodation, and maintain communication after returning home. RovithoMed’s model is designed to coordinate these stages through a single point of contact. Patients can begin remotely by providing relevant information and outlining the treatment they are considering. RovithoMed can then coordinate consultations with appropriate practitioners before travel. Once a treatment plan has been determined by the relevant healthcare professionals, the company can assist with arrangements surrounding the visit, including appointments, accommodation and transfers. The model reflects a wider focus in Turkey on international health services and the experience of patients travelling for treatment. “We have brought dental care, hair treatments, facial aesthetics, dermatology and plastic aesthetic procedures together within one coordinated network,” Ebcim said. “The objective is to make the organisational side of the experience more transparent and manageable for international patients.” RovithoMed said its focus is on developing this coordinated model while maintaining communication between patients, practitioners and supporting services throughout the healthcare travel process.
- August 17, 2026Medicine & Pharmaceuticals
Ace Therapeutics Expands End-to-End CRO Capabilities with Fully Customizable Respiratory Infection Model Development Platform
Ace Therapeutics, a specialized contract research organization (CRO) focused on respiratory and infectious disease preclinical research, unveiled its full-spectrum respiratory infection model development service platform, designed to address unmet translational gaps for researchers advancing novel therapeutics against bacterial, viral, mycobacterial and fungal pulmonary pathogens. The platform centers on tailored study design featuring custom preclinical respiratory infection models, alongside integrated PK/PD analysis capabilities to link drug exposure directly to in vivo therapeutic efficacy. Respiratory infectious diseases remain a persistent global public health burden, with emerging resistant pathogens and complex polymicrobial conditions slowing the translation of early-stage drug candidates into clinical assets. Ace Therapeutics’ new service portfolio resolves this challenge by combining bespoke model engineering with unified multi-parametric endpoint testing for streamlined, data-rich preclinical pipelines. Ace Therapeutics’ custom preclinical respiratory infection models are built to align with clients’ research objectives. Its scientific team customizes every layer of the infection study framework, including pathogen selection (reference strains, clinical isolates, drug-resistant variants, and genetically modified microbes), host animal backgrounds (immunocompetent, neutropenic, genetically edited knockout and humanized rodents, plus alternative species such as cotton rats and tree shrews), infection routes (intranasal, intratracheal, aerosol, oropharyngeal aspiration), and disease progression profiles spanning acute lethal, self-resolving subacute, chronic persistent, and pathogen reactivation phenotypes. Supported model categories cover bacterial pneumonia, viral respiratory illness, mycobacterial tuberculosis-like infection, fungal pulmonary disease, and polymicrobial biofilm-driven chronic lung infection, with standardized and customizable tissue sampling, survival monitoring, and longitudinal burden quantification workflows. To maximize the value of each infection model, Ace Therapeutics offers a comprehensive suite of downstream analyses that can be integrated into clients’ study design, such as microbiological evaluation, immunological profiling, and PK/PD analysis in infection models . Rather than separating pharmacokinetic sampling and efficacy testing across discrete animal trials, Ace Therapeutics conducts coordinated tissue and plasma drug concentration measurements alongside core infection readouts within a single animal cohort. This integrated approach generates direct exposure-response datasets by correlating lung and epithelial lining fluid drug levels with key efficacy endpoints, including microbial CFU or viral titer reduction, survival benefit, lung tissue injury scores and inflammatory cytokine signatures. Ace Therapeutics incorporates rigorous quality control measures across inoculum preparation, animal housing, infection procedures and tissue collection, with matched control groups embedded within every trial to eliminate confounding variables. Post-study deliverables include complete raw datasets, statistical evaluations, high-resolution histology imagery, and consolidated executive reports formatted for internal program review and regulatory submission requirements, with full data ownership and client confidentiality guaranteed. Clients seeking to launch respiratory infectious disease preclinical work can schedule free pre-study consultation sessions with Ace Therapeutics to refine model design, pathogen selection, infection route planning, and endpoint panels before initiating formal in vivo trials. About Ace Therapeutics Ace Therapeutics is a specialized contract research organization delivering tailored preclinical modeling and research services focused on respiratory and infectious disease research. Staffed by veteran respiratory and infection biology scientists, Ace Therapeutics designs reproducible, translational animal models, and integrated analytical workflows to support every stage of antimicrobial, antiviral, antifungal, and immunomodulatory drug development. Its service suite prioritizes custom study design, integrated PK/PD profiling and robust regulatory-grade data generation to accelerate the translation of novel therapeutics addressing global respiratory health threats.
- August 17, 2026Medicine & Pharmaceuticals
Streamlining Proteomic Sample Preparation, Amerigo Scientific Unveils Its Full Suite of Mass Spectrometry Grade Enzymes
The leading provider of critical life science research products and services, Amerigo Scientific, introduced its mass spectrometry grade enzymes engineered to eliminate background artifacts, boost cleavage specificity, and deliver reproducible LC-MS/MS results across all protein analysis workflows. Mass spectrometry grade enzymes represent ultra-purified, chemically modified proteases refined specifically for proteomic digestion and sample preprocessing. Unlike standard lab proteases, these reagents undergo rigorous purification and reductive methylation treatments to suppress non-specific autolysis and off-target proteolytic activity, which prevents unwanted noise peaks and ambiguous signals during mass spectrum acquisition. Amerigo Scientific’s specialized proteolytic enzymes are designed with distinct cleavage profiles to resolve complex protein samples and expand measurable protein sequence coverage. The proteolytic enzyme products span traditional animal-derived and fully recombinant variants to fit diverse research and industrial needs. Flagship offerings include standard trypsin, ultra-fast recombinant Trypsin 3.0, mirror proteases rTrypsin-N and rLys-N, combined rTrypsin/rLys-C complex, rLys-C, rGlu-C, rArg-C, chymotrypsin and rAsp-N. Each protease targets defined amino acid termini—either C-terminal or N-terminal cleavage at arginine, lysine, glutamate, aspartate or aromatic residues—enabling researchers to select single enzymes or sequential digestion combinations to resolve digestion gaps and precisely map post-translational modifications (PTMs) such as phosphorylation, methylation, and glycosylation. These specific proteolytic enzymes serve as foundational tools for protein identification, quantitative proteomics, single-cell research, neurodegenerative disease biomarker study, and biotherapeutic peptide mapping. Complementing the proteomics toolkits, Amerigo Scientific features dedicated glycoproteomics and glycan analysis enzymes tailored for targeted characterization of N-linked and O-linked protein glycosylation, a critical PTM category for antibody drug development and glycoproteomic research. This subset includes O-Glycoprotease for O-glycosylation site profiling, rEndo S2 for IgG Fc glycan cleavage and rPNGase F for universal N-glycan removal. The glycoproteomics and glycan analysis enzymes avoid structural bias toward sialic acid or core fucose residues, supporting intact glycoprotein mass testing, glycan site localization and high-throughput glycan profiling for biopharma quality control pipelines. Beyond protein and glycan processing, Amerigo Scientific expands the mass spectrometry grade enzymes portfolio with auxiliary reagents to address full pre-analytical workflow challenges. Its antibody engineering and conjugation enzymes deliver site-specific cleavage and labeling for therapeutic antibody fragment generation, fusion tag removal, and click chemistry-based protein modification, including IdeS/IdeZ for IgG fragmentation, SUMO protease, enterokinase, and Sortase A. Amerigo Scientific also supplies BenzoNuclease, a universal recombinant endonuclease that eliminates DNA and RNA contaminants to reduce sample viscosity and improve protein recovery before MS analysis, mitigating nucleic acid interference with downstream spectral data. Amerigo Scientific’s product range caters to small academic labs conducting fundamental proteomic research through large biotech cohorts running high-volume therapeutic protein characterization programs. Whether specific proteolytic enzymes or antibody conjugation enzymes, clients can order from Amerigo Scientific’s enzyme shop . About Amerigo Scientific Amerigo Scientific is a leading U.S. distributor of high-performance life science reagents, instruments and consumables for academic research institutes, laboratories, and global biopharmaceutical enterprises. Backed by a team of experienced life science specialists with years of combined industry experience, Amerigo Scientific integrates global top-tier product resources to deliver one-stop analytical solutions for proteomics, glycobiology, antibody engineering, and molecular biology workflows. Its technical support team provides customized protocol consultation to optimize mass spectrometry sample preparation for every customer's unique experimental design.
- August 14, 2026Medicine & Pharmaceuticals
Chronic Lyme Disease & Infertility: Customized Family Treatment Plans Announced
Mercy Family Health and Pain Management now offers customized family treatment plans that address many chronic conditions including chronic Lyme disease and infertility. This approach approaches healing from a family health perspective using natural and holistic approaches. This integrated model departs from conventional care that treats these conditions narrowly without attention to the many issues that affect chronic stress. Instead they are providing a unified family-centered framework where Dr. Stanley Lang's Natural Lyme disease Treatment Program provides multifaceted effective non antibiotic strategies. Sheri Lang's advanced natural infertility care features a unique biology centered approach, a root cause strategy called NaProTechnology. Families facing both conditions have historically lacked integrated treatment options that address the whole family unit rather than isolated individuals. More information is available at https://www.americastruehealth.com/family-practice-family-doctor-dubois The scale and severity of these conditions underscore the need for a broad family centered care. Medical research indicates that 14 to 20 percent of Lyme disease patients continue to experience debilitating symptoms even after appropriate antibiotic treatment, a condition known as Post-Treatment Lyme Disease Syndrome (PTLDS). Separately, infertility affects 10 to 15 percent of couples in the United States, defined as the inability to conceive after one year of unprotected intercourse, or six months for women aged 35 or older. When families confront both conditions concurrently, the compounding challenges create barriers to wellness that conventional, fragmented care models struggle to address effectively. Mercy Family Health and Pain Management has operated since 1981 using a wholistic care model for all family members, from newborns to the elderly. In 1981 it was known as “Agape Family Health Center”. Dr. Stanley Lang brings over 40 years of clinical experience in holistic medicine, treating the family as an interconnected system rather than a collection of isolated patients. This philosophy becomes particularly relevant for families where one member's chronic condition affects reproductive health and family planning, as the ripple effects of illness extend beyond the individual to influence household dynamics, emotional wellbeing, and long-term family goals. The Natural Lyme disease Treatment Program is a self-guided lifestyle and nutritional program that utilizes specific herbal strategies, particularly stevia extracts. Laboratory studies have shown that stevia leaf extract can disrupt Borrelia burgdorferi biofilms and kill various forms of the bacteria, though more research is needed to confirm effectiveness in human patients. Biofilms represent a major factor in persistent Lyme disease, as they shield bacteria from conventional antibiotic therapies. Dr. Lang's program addresses the needs of the 14 to 20 percent of patients who remain symptomatic despite standard treatment protocols, offering a pathway grounded in natural medicine principles that moves beyond antibiotic-dependent approaches. The program is supplemented by in office guidance when necessary. Sheri Lang, a certified registered nurse practitioner, provides advanced natural infertility care through NaProTechnology at Mercy FertilityCare of DuBois. The practice utilizes the Creighton Model FertilityCare System for diagnosis and treatment of gynecologic abnormalities, addressing both infertility and other reproductive health concerns. This broader application demonstrates how natural reproductive health management integrates into family wellness, addressing underlying conditions that affect both fertility and overall quality of life. The customized family treatment plans integrate both services, creating synergies for families managing Lyme disease and infertility together. Coordinating care under one roof eliminates the fragmentation that occurs when patients navigate multiple specialists with differing philosophies. Families receive personalized protocols that account for the interplay between chronic infection, immune function, hormonal balance, and reproductive health, all within a framework that respects natural healing processes and family-centered values. Families experiencing chronic Lyme disease or infertility are invited to contact Mercy Family Health and Pain Management in DuBois, Pennsylvania, to discuss personalized, integrated treatment options. The practice's family-centered, natural approach offers an alternative to conventional-only models for those seeking care that addresses their specific needs. For more details, visit https://www.americastruehealth.com
- August 12, 2026Medicine & Pharmaceuticals
Regenics Launches Physician-Led GLP-1 Membership Program With Lower Medication Pricing
Regenics has launched a new physician-led GLP-1 membership program designed to expand access to medical weight loss care through ongoing clinical oversight and lower medication pricing. The new model replaces simplified bundled programs with a membership structure intended to support continuous supervision by the Regenics medical team. Under the program, patients receive unlimited access to their care team, along with ongoing prescription management, dose adjustments when appropriate, and refill coordination, with treatment plans tailored over time based on physiology, biomarker trends, and long-term health goals. Photo Courtesy of: Regenics Membership starts at $39 for the first month and $79 per month thereafter, providing access to Regenics' physician-led weight management framework. GLP-1 medications are billed separately based on prescribed dose, allowing pricing to change as treatment progresses in line with each patient's clinical needs. Regenics offers semaglutide starting at $119 and tirzepatide starting at $199, with dosing determined by each patient's metabolic response and physician guidance. The program builds on Regenics' physician-led care model, which began at its Los Angeles-area clinic and later expanded through telemedicine to serve patients across the United States. Medical consultations at Regenics continue to be conducted by licensed medical professionals as the company broadens access to supervised GLP-1 treatment. "Biomarkers are the map. Your symptoms are the story. Our job is to bring those two things together," said Phillip Marks, Head Nurse Practitioner at Regenics. In addition to GLP-1 care, members may also access physician-guided therapies such as pharmaceutical-grade peptide protocols, hormone optimization programs, metabolic support treatments, and advanced biomarker testing. The program's weight management care is built around semaglutide and tirzepatide—FDA-approved active ingredients used in leading prescription weight-loss medications, including GLP-1 and dual GIP/GLP-1 therapies. Regenics now includes complimentary medication delivery so prescribed therapies can be shipped directly to patients' homes without added shipping costs. "Patients want more than access to medication," said Elise Easom, COO at Regenics. "They want physician guidance, ongoing support, and care that can adapt as their body and goals change. This membership model allows us to deliver that level of clinical support while improving affordability." Regenics said the membership launch reflects its broader view that medical weight loss should be managed as an ongoing clinical process rather than a one-time transaction. The company noted that more information on the GLP-1 membership structure, pricing, and eligibility criteria is available through its dedicated membership page at regenics.com/membership-landing. About Regenics Regenics is a health and hormone optimization clinic built around physician-led, patient-centered care. The clinic helps individuals improve energy, metabolic function, weight control, sexual health, and long-term health through evidence-based medical protocols and personalized plans grounded in physiology and clinical data. What began as a local practice in Tarzana, California, has grown into one of the fastest-growing clinics in its field, expanding from in-person care in the Los Angeles area to secure telemedicine that now serves patients across the United States, with patient care remaining the constant behind that growth.
- July 30, 2026Medicine & Pharmaceuticals
Dr. Milisha Chotai Receives 2026 Global Recognition Award For Clinically Driven Preventive Dental Innovation
Dr. Milisha Chotai has been honored with a 2026 Global Recognition Award for Smile Boosters™, a dissolvable supplement designed for use between brushing. The award recognizes her evidence-based response to persistent gaps in everyday oral health care and its alignment with modern lifestyles. Photo Courtesy of Milisha Chotai Dr. Chotai received the award in the innovation and startup of the year category for advancing a structured approach to preventive dental care. Drawing on more than two decades of clinical experience, she identified a critical gap in traditional oral hygiene guidance: the extended periods between brushings, during which teeth are repeatedly exposed to food, drink, and environmental factors. Smile Boosters™ was developed as a practical, chairside-informed solution that integrates seamlessly into daily routines without requiring disruption or access to a sink. Her work reflects a broader shift in preventive care, where effectiveness is increasingly measured by how well solutions fit into contemporary habits shaped by frequent snacking, varied diets, and demanding schedules. Clinical Foundations And Professional Path Dr. Chotai’s career combines clinical practice, leadership, and education. As owner and principal dental surgeon at Newnham Dental Practice in Cambridgeshire, she oversees multidisciplinary teams and manages complex restorative and implant cases. Her role requires consistent attention to clinical outcomes, operational processes, and team development. She also contributes to academic advancement as a past honorary lecturer in dental implantology at the University of Bristol, reinforcing her commitment to evidence-based practice and knowledge sharing. Her academic credentials include an MSc in Dental Implantology and an MSc in Medical Education, as well as business certifications from Harvard Business School Online. This combination allows her to bridge clinical rigor with practical implementation, ensuring innovations like Smile Boosters™ are both scientifically grounded and viable in real-world settings. Extensive patient interactions, case studies, and clinical observations shaped the product’s development. Dr. Chotai identified a recurring pattern: patients who adhered to standard brushing advice still experienced preventable issues. By reframing the “between brushing” period as central rather than incidental, she positioned oral supplements as a meaningful extension of daily care. Innovation In Everyday Oral Care Traditional oral care models focus heavily on brushing moments, often overlooking the continuous exposure teeth face throughout the day. Dr. Chotai addressed this limitation by developing a dissolvable supplement that delivers fluoride and xylitol in a convenient, on-the-go format. Designed with patient behavior in mind, Smile Boosters™ enhances existing habits rather than requiring new ones. This approach aligns with growing 2026 industry trends favoring preventive solutions that integrate effortlessly into daily life, improving adherence and long-term outcomes. “Preventive strategies need to reflect how people live now, where time and environment influence consistency more than intention,” Dr. Chotai noted, highlighting the practical foundation behind the product. Global Recognition Awards judges evaluated her submission using criteria such as novelty, market impact, and ability to address global challenges. Her entry achieved top scores across innovation categories. The organization applies the Rasch model to convert evaluations into a standardized measurement scale, enabling consistent comparisons across industries. Final Words “Dr. Milisha Chotai’s work demonstrates how careful clinical insight can inform practical solutions that fit into everyday life,” said Alex Sterling, spokesperson for Global Recognition Awards. Her recognition underscores the importance of translating clinical expertise into accessible tools that improve patient outcomes. By focusing on the often-overlooked hours between brushing, Chotai has helped reshape preventive care frameworks while maintaining a strong foundation in established science. “The ability to connect rigorous clinical practice with accessible, everyday solutions is exactly what this award seeks to recognize,” Sterling added. Dr. Chotai’s journey from clinician to innovator remains rooted in prevention, addressing oral health issues before they become irreversible. Smile Boosters™ encourages both professionals and patients to consider the full daily cycle of oral care, supporting a shift toward more realistic and effective preventive strategies. About Global Recognition Awards Global Recognition Awards is an international organization that honors individuals and companies making meaningful contributions to their industries. Its evaluation framework emphasizes measurable impact, sustained commitment, and the potential to influence broader practices across sectors.
- July 29, 2026Medicine & Pharmaceuticals
New: Survival Skills for Women’s Health Fall 2026 - Experts Teach Menopause
Physicians, nurse practitioners, physician assistants, nurses, and allied healthcare providers in clinical practice looking for the latest information on healthcare of midlife women in perimenopause, menopause and beyond, can register to attend Survival Skills for Women’s Health - Experts Teach Menopause scheduled for November 6-8, 2026. World Class CME is sponsoring this year's event, which will cover key issues such as: Menopausal Hormone Therapy in Breast Cancer Survivors - Explainining the core physiology/pathophysiology of breast cancer (BC), and mechanisms relevant to the use of both local and systemic menopausal hormone therapy (MHT) following primary BC treatment. Understanding selected outcomes from major clinical trials, observational data, and guidelines, emphasizing their strengths/limitations relating to the use of MHT in BC survivors. Distinguishing relative vs absolute risk/benefit (short-term vs long-term) to support accurate clinical interpretation/utilization of MHT in this setting. Translating the data presented into patient selection, counseling, and shared decision-making for prescribing MHT in this setting. Menopausal Hormone Therapy: Where Does the Pendulum Belong - Faculty: James A. Simon, MD - A practical, evidence-based update on menopausal hormone therapy (MHT). The session examines current risk-benefit data, patient selection, timing, regimens, and how clinicians should position MHT in 2026 after two decades of shifting guidance following the Women’s Health Initiative. Testosterone: Myths and Realities - Faculty: James A. Simon, MD - A clear-eyed review of testosterone use in midlife women. Covers evidence for libido, energy, and body composition; common misconceptions; appropriate candidates; dosing and monitoring; and what the data do (and do not) support. Genitourinary Syndrome of Menopause: Yes, Dyspareunia, but Much More - Faculty: Alyse Kelly-Jones, MD - A comprehensive look at GSM beyond painful intercourse. Addresses diagnosis, the full spectrum of genitourinary symptoms, impact on quality of life, and evidence-based hormonal and non-hormonal treatment strategies that generalists can implement immediately. Full details on the event can be found on the company website at https://worldclasscme.com/events/survival-skills-for-womens-health-fall/ . When asked about the reasons behind creating this event, the host of the event, World Class CME said: "It was so great to hear from smart people who were presenting the results of their curiosity and engagement with the information. I felt so energized by the depth of exploration of theory and data." - Meghan Bride, WHNP-BC The World Class CME website has full details about the sessions at this year's event. Interested parties can visit the website at: https://worldclasscme.com/events/survival-skills-for-womens-health-fall/ .
- July 29, 2026Medicine & Pharmaceuticals
Novadose & Pure Pharmaceuticals Driving the Future of Peptide Science
As demand for pharmaceutical-grade peptides continues to accelerate worldwide, two companies are making a significant investment in what they believe will become the industry’s most valuable currency trust. The global peptide industry is experiencing unprecedented growth. As scientific research advances and manufacturing capabilities evolve, expectations surrounding product quality, traceability and regulatory compliance are rising just as rapidly. Against this backdrop, Novadose and Pure Pharmaceutical have announced a strategic partnership aimed at redefining standards across peptide manufacturing and supply-chain transparency. While financial details remain undisclosed, the companies confirm they are making a substantial long-term investment into next-generation peptide manufacturing, advanced quality systems and research-driven process development. The objective is clear: to deliver consistently high-purity peptides supported by comprehensive quality assurance and documented traceability throughout every stage of production. Industry observers note that the peptide sector is entering a period where manufacturing excellence is becoming just as important as scientific innovation. Increasingly, customers and partners want more than certificates of analysis. They expect confidence that every stage of production—from raw materials and analytical testing to logistics and final delivery—has been managed to the highest possible standard. According to representatives from the partnership, this philosophy has become the foundation of the collaboration. “Transparency should never begin with the finished product. It should begin at inception and continue throughout manufacturing, quality assurance, logistics and delivery.” Pure Pharmaceutical will contribute pharmaceutical-quality manufacturing processes, stringent quality management systems and end-to-end production traceability. Novadose will focus on delivering that manufacturing excellence through a customer-first approach built around reliability, consistency and confidence. The announcement comes at a time when expectations across the life sciences sector continue to evolve. As quality requirements become increasingly rigorous, manufacturers capable of demonstrating—not simply claiming—operational excellence are expected to distinguish themselves in an increasingly competitive market. Rather than competing on volume alone, Novadose and Pure Pharmaceutical say their long-term strategy is centred on scientific investment, manufacturing precision and complete transparency throughout the supply chain. Whether this approach will influence broader industry standards remains to be seen, but one message is already clear: the conversation surrounding peptide manufacturing is changing. In the years ahead, success may depend less on who can manufacture the most—and more on who can demonstrate the highest standards of quality, accountability and trust. Novadose × Pure Pharmaceutical Raising the Standard. From Inception
- July 29, 2026Medicine & Pharmaceuticals
Most Utah Deaths Never Reach the State Medical Examiner. Postmortem Pathology Offers Salt Lake City Families a Private Autopsy Option.
Roughly two out of every three deaths in Utah never come under the authority of the state Office of the Medical Examiner, which leaves thousands of families each year without a public route to a postmortem examination. Postmortem Pathology, a nationwide practice offering private autopsy services in Salt Lake City and across the Wasatch Front, exists to close that gap. State medical examiner authority in Utah reaches only a fraction of deaths, somewhere near one in three. The office logged 7,899 death investigations over the course of 2023. Its mandate covers deaths that arrive without warning, involve violence, or carry circumstances no physician can readily explain. Even inside that mandate, a full autopsy is not automatic. What remains is a large category of Utah families standing outside the system altogether. A parent dies in an assisted living facility. A relative is certified as a natural death while the family suspects a diagnosis was missed. A sudden cardiac death raises the question of whether surviving children carry the same inherited risk. In each case, a private autopsy in Salt Lake City is frequently the only way forward. "Families come to us because the question they are asking is not the question the state system is built to answer," said Dr. Dan Lingamfelter, lead pathologist at Postmortem Pathology. "A death can be entirely expected from a legal standpoint and still leave a family with no idea what actually happened medically. That gap is where we work." Timing matters as much as access. For families working against probate deadlines, insurance filing windows, or civil claims governed by fixed limitation periods, an independent autopsy in Salt Lake City can be booked directly and delivered on an agreed schedule. Record access is a third consideration. Utah statute shields medical examiner files from open release. Attorneys who want them must first establish standing, ordinarily through written authorization from the legal next of kin, appointment by a court as representative of the estate, or a subpoena or order issued by a judge. An examination commissioned privately produces a report that belongs to the family or their counsel from day one. Postmortem Pathology is run by pathologists holding board certification in anatomic, clinical, and forensic pathology, with case experience spanning criminal and civil proceedings. A standard examination covers inspection of the body inside and out, screening for drugs and toxins, and microscopic study of tissue. Pricing opens at $5,000. Findings stay confidential and are released only to the family or the parties they designate. Families and attorneys pursuing a private autopsy in Salt Lake City can contact Postmortem Pathology directly to review case specifics, scheduling, and coordination with whichever funeral home or facility currently holds the decedent. About Postmortem Pathology Postmortem Pathology is a private autopsy and forensic pathology practice staffed by pathologist’s board certified in anatomic, clinical, and forensic pathology. The firm handles cases in all 50 states, including private autopsy services in Salt Lake City and throughout Utah, working with families, attorneys, insurers, and treating physicians. More information is available at postmortempath.com.
- July 24, 2026Medicine & Pharmaceuticals
Ace Therapeutics Introduces Validated Custom Animal Models to Support Cardiac Ischemia-Reperfusion Research
Global preclinical CRO Ace Therapeutics expands its cardiovascular disease model portfolio with fully validated myocardial ischemia-reperfusion (MI/R) animal modeling services, equipping academic labs and biopharma developers with reproducible research tools to advance ischemic cardiomyopathy therapeutic discovery. Surgical coronary artery ligation remains the gold-standard method to recapitulate human heart attack and reperfusion therapy pathology. Ace Therapeutics optimizes every procedural step for consistent, customizable model generation. Under deep anesthesia, Ace Therapeutics’ experts perform thoracotomy, temporary ligation of the left anterior descending coronary artery, timed ischemia incubation, suture release for reperfusion, followed by chest closure and layered skin closure. Post-operative continuous animal monitoring mitigates infection, organ failure, and premature mortality, ensuring intact study cohorts for long-term efficacy and mechanistic readouts. The custom coronary artery ligation MI/R models cover a broad panel of validated animal strains to match diverse research design requirements, including C57BL/6 and BALB/c mice, SD and Wistar rats, alongside New Zealand white and Japanese white rabbits. Rigorous multi-layered model validation protocols guarantee a reliable ischemic injury phenotype: real-time intraoperative ECG monitoring tracks ST-segment elevation as an immediate marker of successful coronary occlusion, while terminal myocardial tissue harvest paired with TTC-Evans blue dual staining enables precise quantitative calculation of infarct area, delivering objective histological endpoints for drug comparison. As scalable preclinical anti-ischemic drug efficacy evaluation models, these MI/R models support full-spectrum research workflows ranging from basic mechanistic pathway exploration to candidate compound pharmacodynamic screening. Researchers leverage the standardized surgical models to investigate signaling pathways governing ischemic preconditioning and reperfusion cytoprotection, quantify drug-mediated reductions in infarct size, and assess therapeutic impacts on oxidative stress, inflammatory signaling, and cardiomyocyte survival. All modeling procedures align with published cardiovascular research frameworks and peer-reviewed experimental protocols, delivering comparable, publication-quality datasets for preclinical IND-enabling studies. Ace Therapeutics has long specialized in custom cardiovascular disease animal model development, maintaining a full-service platform spanning atherosclerosis, hypertension, thrombosis, heart failure, and now refined MI/R injury systems. The launch of its standardized validated custom MI/R models fills a critical gap for partners seeking turnkey, validated preclinical anti-ischemic drug efficacy evaluation models without the resource burden of in-house surgical model optimization. Its integrated service package covers full model construction, intraoperative physiological monitoring, post-operative animal care, tissue collection, histochemical staining, and quantitative infarct analysis, streamlining end-to-end cardiovascular preclinical testing. Investigators and pharmaceutical developers focused on myocardial protection, anti-infarction, and reperfusion injury therapies can access Ace Therapeutics' complete animal models of cardiovascular disease for customized study design. Its cross-disciplinary team of cardiovascular pharmacologists, veterinary surgeons, and pathologists tailors model parameters—including ischemia duration, reperfusion timeline, and species selection—to match unique research hypotheses and drug development milestones. About Ace Therapeutics Ace Therapeutics is a leading provider of cardiovascular basic research services and custom preclinical animal model development. Its comprehensive disease model library enables translational research and drug efficacy assessment for ischemic heart disease, metabolic cardiovascular disorders, and chronic heart failure, supporting global academic institutions, biotech startups, and pharmaceutical enterprises in advancing novel cardiovascular therapeutics.
ALL NEWS
- AUX Makes Its IFA Debut, Bringing AI-Powered Air Solutions to Berlin
- Abundant Redundant Announces Redundancy Exit Planning Resources for Women Navigating Workplace Change
- Hudson Hedge Capital Provides Strategic Development Update on CINV
- IJPBooks.com Announces The Republic We Share, Exploring Religious Liberty and Common Ground in America
- Wigsretail44 Announces Expanded Wig Selection for Personal Style and Everyday Hair Expression
- New Global Heart Hub report calls for stronger patient partnership to accelerate cardiovascular action in Asia Pacific region
- ORI Future Showcases Its Connected Home-Bar Ecosystem at IFA Berlin 2026
- CaoCao Teams Up with Doubao to Launch AI Ride-Hailing Service, with Initial Rollout in Beijing, Hangzhou and Suzhou
- With the Golden Key Lighting the Way—the 26th CIFIT Open
- “Tea Chat with Ambassadors in Shanxi” & International Dialogue on Energy and Low-carbon Development Successfully Held in Taiyuan
- Kandao Technology Introduces Meeting Pro 2 to Rethink Audio for Better Hybrid Meetings
- How to Choose an HVAC Company in West Palm Beach
- How to Choose an HVAC Company in San Antonio
- 4 AI Tools for Character Singing in 2026: A Creator Workflow Comparison
- Phony.ai Launches Provider-Neutral AI Phone and Voice Agent Platform
- HARRY POTTER: VISIONS OF MAGIC ARRIVES IN CHINA, MAKING ITS DEBUT IN CHENGDU OPENING 4TH QUARTER OF 2026
- HARRY POTTER: VISIONS OF MAGIC ARRIVES IN CHINA, MAKING ITS DEBUT IN CHENGDU OPENING 4TH QUARTER OF 2026
- CyberAttack.ai Launches AI-Native Cybersecurity Platform for Continuous Threat Detection and Remediation
COMMUNICATE. COMMAND. COMMERCE.
Lead the conversation of your brand & win more customers with MarketersMEDIA Solutions.
Explore Now
Google
RSS